Recovery Narrative Meets Hard Math — Q1 Shortfall Strains FY27 Guidance

The profit recovery is real—it's a rebound from Q1 FY26, crushed by the Hyderabad incident that idled the Dahej facility. But that facility is still running at only 76.5% utilization, and Jhagadia at 77.16%. MCC pricing has climbed to ₹241 per kg (+11.7% quarter-on-quarter), yet total revenue fell 5.4% year-on-year. That gap—pricing power meeting volume weakness—defines the quarter's tension.

Sigachi maintained FY27 guidance at ₹650–675 Crore. Divided by four quarters, that implies a quarterly run-rate of ₹162–169 Crore (low to high end), or ₹165.6 Crore at the mid-point. Q1 delivered ₹121.3 Crore—a shortfall of ₹44.3 Crore, or 26.8% below even the low-end quarterly average. For FY27 to hold, Q2 onwards must average ₹176+ Crore per quarter—a 45% acceleration from Q1. Management called this 'small variations' and promised 'second-half improvement,' but offered no monthly or quarterly phasing to show how that acceleration will happen. On the call, multiple analysts pressed on this math: if capacity utilization is 76.8% and Q1 revenue fell short by ₹44 Crore, how does the company close the gap? Management deflected with product-mix and debottlenecking claims but never reconciled the numbers.

Three shifts: (1) MCC expansion timeline slipped. The 12,000 MTPA facility at Dahej-2 now commissions in Q2 FY28, not Q1 FY28—a one-quarter delay with no FY27 revenue impact, contrary to prior hope it would contribute. (2) API target lifted. New molecules (Sparsentan, Bempedoic Acid, Zestrapin) added to pipeline; FY27 target upped to >₹100 Crore from prior ₹90–100 Crore. But evidence remains absent—Q1 only ₹21.68 Crore, and management has not named customers, disclosed supply contracts, or proven >₹25 Crore quarterly traction. (3) CCS timeline firmed at Q2 FY28. The 1,800-ton cellulose sulfate facility will commission by Q2 FY28, with 25%+ target margins. Pre-launch inquiries from export pharma customers noted, but no signed agreements disclosed, and zero contribution expected in FY27.

The stock sits at ₹30.31, well above key moving averages (SMA20 ₹26.64, SMA50 ₹24.7, SMA200 ₹25.42). From its all-time high of ₹40.8, it has fallen 25.7%—a meaningful drawdown signaling investor caution, yet the stock is up 82% off its 52-week low of ₹16.65. RSI at 68.5 is neutral (neither overbought nor oversold). Volume is increasing, a positive conviction signal. On the flows side: FII trimmed from 1.30% to 1.25% in Q1 FY27, a 5 basis point outflow. DII remains absent at 0%. Promoter stable at 36.69%. The slight FII retreat post-result is subtle but meaningful—institutions are not buying the recovery narrative aggressively. The price action (up from lows, down from highs, rising volume) mirrors the fundamental read: the recovery story is pricing in, but Q1's miss and unresolved guidance math temper enthusiasm. A meaningful re-rating higher would require proof of two things: (1) Q2+ revenues hitting ₹155+ Crore and utilization reaching 85%+, and (2) API scaling showing ₹25+ Crore quarterly run-rate with verifiable customer traction.